Combination gene therapy: Synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule

Human Gene Therapy

Volumn 11, Issue 6, 2000, Pages 807-815

  Lisziewicz, Julianna ^a,b   Zeng, Gang ^a,b,c   Gratas, Catherine ^a,b   Weinstein, John N ^c   Lori, Franco ^a,b  

^a Research Institute for Genetic and Human Therapy   (United States)

^b Research Institute for Genetic and Human Therapy (RIGHT)   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REV PROTEIN; RNA; TRANSACTIVATOR PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; VIRUS INHIBITION;

CELL LINE; GENE PRODUCTS, REV; GENE PRODUCTS, TAT; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HIV; HUMANS; NUCLEIC ACID CONFORMATION; RNA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0034630336     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015428     Document Type: Article

References (34)

1. ALAM, J., and COOK, J.L. (1990). Reporter genes: Application to the study of mammalian gene trancription. Anal. Biochem. 188, 245-254.
2. BAHNER, I., KEARNS, K., HAO, Q.L., SMOGORZEWSKA, E.M., and KOHN, D.B. (1996). Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J. Virol. 70, 4352-4360.
3. BAUER, G., VALDEZ, P., KEARNS, K., BAHNER, I., WEN, S.F., ZAIA, J.A., and KOHN, D.B. (1997). Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89, 2259-2267.
4. BERENBAUM, M.C. (1977). Synergy, additivism and antagonism in immunosuppression. Clin. Exp. Immunol. 28, 1-18.
5. BOIX, V., REUS, S., PRIEGO, M., MERINO, E., ROMAN, F., CLIMENT, E., and PORTILLA, J. (1998). Expanding the spectrum of protease inhibitors-induced lipodistrophy. Int. Conf. AIDS 12, 93. [Abstract 12398]
6. CAPUTO, A., ROSSI, C., BOZZINI, R., BETTI, M., GROSSI, M.P., BARBANTI-BRODANO, G., and BALBONI, P.G. (1997). Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication. Gene Ther. 4, 288-295.
7. CARA, A., GUARNACCIA, F., REITZ, M., GALLO, R., and LORI, F. (1995). Self-limiting, cell-type dependent replication of an integrase defective HIV-1 in human macrophages but not in human T-lymphocytes. Virology 208, 646-650.
8. CHANG, H.K., GENDELMAN, R., LISZIEWICZ, J., GALLO, R.C., and ENSOLI, B. (1994). Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: A strategy for control of HIV-1. Gene Ther. 1, 208-216.
9. CHINEN, J., AGUILAR-CORDOVA, E., NG-TANG, D., LEWIS, D.E., and BELMONT, J.W. (1997). Protection of primary human T cells from HIV infection by Trev: A transdominant fusion gene. Hum. Gene Ther. 8, 861-868.
10. CHOU, T.C., and TALALAY, P. (1981). Generalized equations for the analysis of inhibitions of Michaelis - Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115, 207-216.
11. CORBEAU, P., and WONG-STAAL, F. (1998). Anti-HIV effects of HIV vectors. Virology 243, 268-274.
12. DUAN, L., ZHU, M., OZAKI, I., ZHANG, H., WEI, D.L., and POMERANTZ, R.J. (1997). Intracellular inhibition of HIV-1 replication using a dual protein-and RNA-based strategy. Gene Ther. 4, 533-543.
13. GILBOA, E., and SMITH, C. (1994). Gene therapy for infectious diseases: The AIDS model. Trends Genet. 10, 139-144.
14. GRAHAM, F.L., and VAN DER ERB, A.J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52, 456-467.
15. GRECO, W.R., BRAVO, G., and PARSONS, J.C. (1995). The search for synergy: A critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385.
16. HUANG, X.J., HOPE, T.J., BOND, B.L., McDONALD, D., GRAHL, K., and PARSLOW, T.G. (1991). Minimal Rev-response element for type 1 human immunodeficiency virus. J. Virol. 65, 2131-2134.
17. INOUYE, R.T., DU, B., BOLDT-HOULE, D., FERRANTE, A., PARK, I.W., HAMMER, S.M., DUAN, L., GROOPMAN, J.E., POMERANTZ, R.J., and TERWILLIGER, E.F. (1997). Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. J. Virol. 71, 4071-4078.
18. LIBERATORE, C., CAPANNI, M., ALBI, N., VOLPI, I., URBANI, E., RUGGERI, L., MENCARELLI, A., GRIGNANI, F., and VELARDI, A. (1999). Natural killer cell-mediated lysis of autologous cells modified by gene therapy. J. Exp. Med. 189, 1855-1862.
19. LISZIEWICZ, J. (1996). TAR decoys and trans-dominant gag mutant for HIV-1 gene therapy. Antibiot. Chemother. 48, 192-197.
20. LISZIEWICZ, J., RAPPAPORT, J., and DHAR, R. (1991). Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol. 3, 82-89.
21. LISZIEWICZ, J., SUN, D., SMYTHE, J., LUSSO, P., LORI, F., LOUIE, A., MARKHAM, P., ROSSI, J., REITZ, M., and GALLO, R.C. (1993). Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc. Natl. Acad. Sci. U.S.A. 90, 8000-8004.
22. LISZIEWICZ, J., SUN, D., LISZIEWICZ, A., and GALLO, R.C. (1995a). Antitat gene therapy: A candidate for late-stage AIDS patients. Gene Ther. 2, 218-222.
23. LISZIEWICZ, J., SUN, D., TRAPNELL, B., THOMSON, M., CHANG, H.K., ENSOLI, B., and PENG, B. (1995b). An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J. Virol. 69, 206-212.
24. LISZIEWICZ, J., SUN, D., GALLO, R.C., ENSOLI, B., and LORI, F. (1996). Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines. Hum. Gene Ther. 7, 2209-2216.
25. LORI, F., HALL, L., LUSSO, P., POPOVIC, M., MARKHAM, P., FRANCHINI, G., and REITZ, M.S., JR. (1992). Effect of reciprocal complementation of two defective human immunodeficiency virus type 1 (HIV-1) molecular clones on HIV-1 cell tropism and virulence. J. Virol. 66, 5553-5560.
26. McCUNE, J.M., RABIN, L.B., FEINBERG, M.B., LIEBERMAN, M., KOSEK, J.C., REYES, G.R., and WEISSMAN, I.L. (1988). Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53, 55-67.
27. RIDDELL, S.R., ELLIOTT, M., LEWINSOHN, D.A., GILBERT, M.J., WILSON, L., MANLEY, S.A., LUPTON, S.D., OVERELL, R.W., REYNOLDS, T.C., COREY, L., and GREENBERG, P.D. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med. 2, 216-223.
28. ROSENZWEIG, M., MARKS, D.F., HEMPEL, D., LISZIEWICZ, J., and JOHNSON, R.P. (1997). Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. J. Virol. 71, 2740-2746.
29. SYMENSMA, T.L., GIVER, L., ZAPP, M., TAKLE, G.B., and ELLINGTON, A.D. (1996). RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo. J. Virol. 70, 179-187.
30. SYMENSMA, T.L., BASKERVILLE, S., YAN, A., and ELLINGTON, A.D. (1999). Polyvalent Rev decoys act as artificial Rev-responsive elements. J. Virol. 73, 4341-4349.
31. VANDENDRIESSCHE, T., CHUAH, M.K.L., and MORGAN, R.A. (1994). Gene therapy for acquired immunodeficiency syndrome. In AIDS Updates. (V.T. DeVita, S. Hellman, and S.A. Rosenberg, eds. (J.B. Lippincott, New York).
32. WALTER, A.E., TURNER, D.H., KIM, J., LYTTLE, M.H., MULLER, P., MATHEWS, D.H., and ZUKER, M. (1994). Coaxial stacking of helixes enhances binding of oligoribonucleotide s and improves predictions of RNA folding. Proc. Natl. Acad. Sci. U.S.A. 91, 9218-9222.
33. WEBB, J.L. (1963). Effect of more than one inhibitor. In Enzymes and Metabolic Inhibitors. (Academic Press, New York) Vol. 1, pp. 66-79, 487-512.
34. ZUKER, M. (1989). On finding all suboptimal foldings of an RNA molecule. Science 244, 48-52.